1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
(
- Contribution to journal › Article
- 2017
-
Mark
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry
(
- Contribution to journal › Article
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
- 2016
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
- 2015
-
Mark
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
(
- Contribution to journal › Article
- 2012
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
- 2011
-
Mark
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
(
- Contribution to journal › Article
- 2010
-
Mark
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.
(
- Contribution to journal › Article
-
Mark
BCL2 expression in de novo Diffuse Large B-cell Lymphoma partly reflects normal differences in age distribution
(
- Contribution to journal › Letter